Literature DB >> 9340955

[Comparative evaluation of a German version of the Health Assessment Questionnaire and the Hannover Functional Capacity Questionnaire].

J Lautenschläger1, W Mau, T Kohlmann, H H Raspe, F Struve, W Brückle, H Zeidler.   

Abstract

OBJECTIVE: To translate the Health Assessment Questionnaire Disability Index (HAQ) into a German version, to validate and to compare its properties with two different versions of the Hannover Functional Ability Questionnaire (HFAQ) in a German speaking population.
METHODS: The test-retest reliability was tested by Pearson correlation in 32 outpatients of the Department of Rheumatology of the Medizinische Hochschule Hannover. For retesting, the questionnaire was mailed to them 1 week later. To validate the questionnaire it was administered to 110 inpatients in three different hospitals. All patients fulfilled the American College of Rheumatology 1987 revised criteria of rheumatoid arthritis (RA) or the Rome criteria of definitive inactive RA. The internal consistency was measured by Cronbach's coefficient alpha (CCA). To assess criterion validity we compared the HAQ and the two versions of the HFAQ with Keitel's test (KT) and the modified Steinbrocker classification (mSC). Construct validity was assessed by comparing these instruments with different clinical and laboratory variables. A multivariate analysis was used to identify the most important factors that are influencing the HAQ- and HFAQ-scores.
RESULTS: Test-retest reliability of the HAQ was r = 0.94. CCA was 0.91 (HAQ), 0.90 (HFAQ-P) and 0.93 (HFAQ-PR). The KT Pearson correlation coefficients reached r = -0.73 (HAQ), r = +0.74 (HFAQ-P) and r = +0.71 (HFAQ-PR). The mSC correlated r = +0.75 (HAQ), r = -0.72 (HFAQ-P) and r = -0.70 (HFAQ-PR). The correlation coefficients of HAQ/HFAQ-P was r = -0.87 and of HAQ/HFAQ-PR r = -0.88. The correlations between other clinical and laboratory variables reached from r = +/-0.58 (pain/HAQ) to r = +/-0.11 (number of swollen joints/HFAQ-PR). In backward multiple regression analysis 59-64% of the variance of disability measured by the questionnaires was explained predominantly by pain (32-33%) and by range of motion (16-21%).
CONCLUSION: The German version of the HAQ presented here and the two versions of the HFAQ are reliable and valid instruments for measuring functional disability in a German-speaking population with RA. The construct measured by the HAQ and both versions of the HFAQ showed a high degree of correspondence.

Entities:  

Mesh:

Year:  1997        PMID: 9340955     DOI: 10.1007/s003930050030

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  57 in total

1.  [Rehabilitation of rheumatic diseases].

Authors:  Ernst Wagner
Journal:  Wien Med Wochenschr       Date:  2003

2.  Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency.

Authors:  Peter K Schädlich; Henning Zeidler; Angela Zink; Erika Gromnica-Ihle; Matthias Schneider; Christoph Straub; Josef G Brecht; Eduard Huppertz
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Expressing treatment-associated changes.

Authors:  S Chrubasik; C Conradt; A Black
Journal:  Z Rheumatol       Date:  2005-09       Impact factor: 1.372

4.  High variability in glucocorticoid starting doses in patients with rheumatoid arthritis: observational data from an early arthritis cohort.

Authors:  Katinka Albrecht; Johanna Callhoff; Matthias Schneider; Angela Zink
Journal:  Rheumatol Int       Date:  2015-02-08       Impact factor: 2.631

5.  [International classification of functioning, disability and health and its significance for rheumatology].

Authors:  J Braun; J Zochling; E Grill; W Liman; G Stucki
Journal:  Z Rheumatol       Date:  2007-11       Impact factor: 1.372

6.  [Trends in rehabilitation of patients with rheumatic diseases in Germany].

Authors:  W Mau; W Beyer; I Ehlebracht-König; J-M Engel; E Genth; W H Jäckel; U Lange; K Thiele
Journal:  Z Rheumatol       Date:  2014-03       Impact factor: 1.372

Review 7.  [Self-monitoring in inflammatory rheumatic diseases].

Authors:  C Kampling; G Chehab; M Schneider; J G Richter
Journal:  Z Rheumatol       Date:  2014-10       Impact factor: 1.372

8.  [Rehabilitation and outpatient physiotherapy in rheumatic disease patients. Results of cross-sectional studies of patients with rheumatoid arthritis or ankylosing spondylitis and rheumatologists].

Authors:  W Mau; A Müller
Journal:  Z Rheumatol       Date:  2008-11       Impact factor: 1.372

9.  [Evaluation of effectiveness of education in rheumatology : Recommendations according to a patient education model].

Authors:  A Reusch; G Musekamp; R Küffner; M Dorn; J Braun; I Ehlebracht-König
Journal:  Z Rheumatol       Date:  2017-09       Impact factor: 1.372

10.  Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.

Authors:  Anja Strangfeld; Franka Hierse; Rolf Rau; Gerd-Ruediger Burmester; Brigitte Krummel-Lorenz; Winfried Demary; Joachim Listing; Angela Zink
Journal:  Arthritis Res Ther       Date:  2010-01-08       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.